



April 27, 2017

Alnylam to Webcast Conference Call Discussing First Quarter 2017 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- [Alnylam Pharmaceuticals, Inc.](http://www.alnylam.com) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2017 on Friday, May 5, 2017, before the U.S. financial markets open.

Management will provide an update on the company and discuss first quarter 2017 results as well as expectations for the future via conference call on Friday, May 5, 2017 at 8:30 a.m. ET. To access the call, please dial 877-312-7507 (domestic) or 631-813-4828 (international) five minutes prior to the start time and refer to conference ID 13425320. A replay of the call will be available beginning at 11:30 a.m. ET on the day of the call. To access the replay, please dial 855-859-2056 (domestic) or 404-537-3406 (international), and refer to conference ID 13425320.

A live audio webcast of the call will be available on the Investors section of the company's website, www.alnylam.com. An archived webcast will be available on the Alnylam website approximately two hours after the event.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform and deep pipeline of investigational medicines, including three product candidates that are in late-stage development or will be in 2017. Looking forward, Alnylam will continue to execute on its "Alnylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20170427005151/en/>

Alnylam Pharmaceuticals, Inc.

Christine Regan Lindenboom, 617-682-4340
(Investors and Media)

or
Josh Brodsky, 617-551-8276
(Investors)

Source: Alnylam Pharmaceuticals, Inc.

News Provided by Acquire Media